



Human CTLA-4 Monoclonal Antibody (Research Grade Ipilimumab Biosimilar)

Recombinant Monoclonal Human IgG1 Clone #FB024

Catalog Number: BIO-016

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CTLA-4 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Ipilimumab. This product is for research use only.
Source	Recombinant Monoclonal Human IgG1 Clone #FB024
Purification	Protein A/G purified from CHO cell culture supernatant
Immunogen	Human CTLA-4
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method
Formulation	0.2 µm filtered solution in PBS

APPLICATION

	Recommended Concentration
Flow Cytometry	0.25 µg/10 ⁶ cells

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/ml in sterile 1xPBS
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none">• 12 months from the date or receipt, -20 to -70°C as supplied.• 1 month, 2 to 8°C under sterile conditions

BACKGROUND

Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).⁵ Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.